{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.555","value":"-0.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"}],"units":"Participants"}],"title":"24 weeks after first course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.556","value":"-0.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"386"}],"units":"Participants"}],"title":"24 weeks after second course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.532","value":"-0.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"}],"units":"Participants"}],"title":"24 weeks after third course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.529","value":"-0.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"}],"units":"Participants"}],"title":"24 weeks after fourth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.541","value":"-0.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"}],"units":"Participants"}],"title":"24 weeks after fifth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.600","value":"-0.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"title":"24 weeks after sixth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.576","value":"-0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"24 weeks after seventh course"}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"}],"units":"Participants"}],"description":"The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab 1 gram IV on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid \\>=5 mg/week or equivalent. Participants received retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first \\[Day 1\\] infusion of the last course of rituximab). Repeat treatment was based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints \\>=2.6). Retreatment with rituximab was continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever occurred earlier.","id":"OG000","title":"Rituximab"}],"paramType":"MEAN","populationDescription":"ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome. Number analyzed = participants who were evaluable for specified category.","reportingStatus":"POSTED","timeFrame":"24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)","title":"Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course","type":"SECONDARY","unitOfMeasure":"units on a scale"}